𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

✍ Scribed by Edward T. Creagan; David L. Ahmann; Stephen Frytak; Harry J. Long; M. N. Chang; Loretta M. Itri

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
691 KB
Volume
59
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

A phase I study of recombinant human int
A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma
✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN